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Abstract
The management of aortic stenosis has improved and evolved to a reduction in 
surgical aggression. Nowadays, patients with intermediate risk are in the frontier 
of transcatheter aortic valve implantation (TAVI) and aortic valve replacement 
(AVR). Our goal is to update the treatment of severe aortic stenosis in those 
patients through a research of the recent literature, in order to analyze the current 
treatment options and their results. This cohort of patients has two therapeutic 
options, surgical AVR or TAVI, and the decision pathway goes through the accurate 
interpretation of all data by the Heart Team. It is clear that both strategies will be 
the cornerstones in the modern AVR era, but the situations in which to apply each 
strategy have not yet been clearly delineated. More studies are needed to compare 
TAVI and miniAVR in low- and intermediate-risk patients. However, the current 
practice guidelines give a good pathway to choose the adequate therapeutic option 
in each individual case.
Keywords: aortic stenosis, aortic stenosis surgery, aortic stenosis management, 
aortic stenosis open heart surgery, aortic stenosis treatment, aortic stenosis valve 
replacement, TAVR procedure, TAVR approaches, TAVR access sites, TAVR, TAVI
1. Introduction
Aortic stenosis is the most frequent valve disease leading to intervention in 
developed countries, either surgery or catheter, and its incidence increases due to 
the aging population [1].
The management of aortic stenosis has improved and evolved to a reduc-
tion in surgical aggression. Nowadays, the patients with intermediate risk are in 
the frontier of transcatheter aortic valve implantation (TAVI) and aortic valve 
replacement (AVR) and more than ever, the heart team has to be more accurate 
to choose between the different treatment options available, making the decision 
pathway more complex than a few year before. Our goal is to update the treatment 
of severe aortic stenosis in those patients where risk assessment scales indicate 
an intermediate risk. Here, we analyze the current treatment options and their 
results.
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2. Etiology and natural history
Nowadays, degenerative calcific AS is the most common cause of AS in adults 
at older ages and represents the leading cause for aortic valve intervention [2–4]. In 
the other hand, bicuspid aortic valve affects 2% of the population and represents 
the most common indication for intervention at younger patients [5].
The development of symptoms identifies a paramount point in the natural 
history of AS, and the interval from the onset of symptoms to the time of death is 
approximately 2 years in patients with heart failure, 3 years in those with syncope, 
and 5 years in those with angina, with a high risk of sudden death [6].
3. Evaluation and severity classification of aortic stenosis
Careful exploration for the presence of symptoms (shortness of breath on 
exertion, angina, dizziness, or syncope) is very important for right patient man-
agement. The characteristic systolic murmur draws attention and guides further 
diagnostic work in the right direction.
Echocardiography is the key diagnostic tool [7]. It discriminates the degree 
of valve calcification, LV function, and wall thickness; helps to identify other 
associated valve diseases or aortic pathology; and provides prognostic information. 
The severity of the stenotic lesion can be defined with Doppler echocardiographic 
measurements. Transoesophageal echocardiography (TOE) provides additional 
evaluation of concomitant mitral valve abnormalities, and become useful when 
transthoracic visualization is poor [8]. TOE has gained importance in the assess-
ment and intraprocedure guidance and after TAVI or surgical interventions.
Three-dimensional TOE offers a more detailed examination of valve anatomy 
than two-dimensional echocardiography and is useful for the assessment and plan-
ning of complex valve problems [8]. AS severity could be graded on the basis of a 
variety of hemodynamic and natural history data as shown in Table 1.
Multislice computed tomography (MSCT) and cardiac magnetic resonance 
(CMR) give additional data on the assessment of the ascending aorta when it is 
enlarged or to quantifying the valve area, coronary calcification, size and shape of 
the aortic valve annulus, and its distance to the coronary ostia, which aids in evalu-
ation and prognosis. It is essential to evaluate the feasibility of the various access 
routes for TAVI, as this provides information on minimal luminal diameters, athero-
sclerotic plaque burden, the presence of aneurysms or thrombi, etc. [8]. MSCT 
plays an important role in the diagnostic work-up before transcatheter aortic valve 
implantation. The risk of radiation exposure—and of renal failure due to contrast 
injection—should, however, be taken into consideration.
Peak velocity (m/s) ≥4
Mean gradient (mmHg) ≥40
Indexed AVA (cm2/m2) <0.6
AVA (cm2) <1
Velocity ratio <0.25
Based on the recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the 
European Association of Cardiovascular Imaging and the American Society of Echocardiography [9].
Table 1. 
Severe aortic stenosis measurement by echocardiography. The definitions apply only in the presence of normal 
flow conditions.
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In patients with inadequate echocardiographic quality or discrepant results, 
CMR should be used to assess the severity of valvular lesions and to assess ventricu-
lar volumes and systolic function [8].
In physically active patients, an exercise testing could be recommended for 
unmasking symptoms and for risk stratification of asymptomatic patients [10]. 
Also, exercise stress echocardiography may give prognostic information in asymp-
tomatic severe aortic stenosis [10, 11]. In some patients, it may be necessary to 
proceed with cardiac catheterization and coronary angiography at the time of initial 
evaluation [7].
Biomarkers. Several studies [12–15] report that biomarkers such as B-type 
natriuretic peptide (BNP) have been shown to be related to functional class and 
prognosis, particularly in AS and MR. Natriuretic peptides have been shown to 
predict symptom-free survival and outcome in normal- and low-flow severe AS and 
may be useful in asymptomatic patients, helping to discriminate those patients who 
can benefit from an early intervention [13–15]. In fact, in the last ESC/EACTS guide-
lines for the management of valvular heart disease, natriuretic peptides may be of 
value for risk stratification and timing of intervention, particularly in asymptomatic 
patients (“markedly elevated BNP levels (>threefold age- and sex-corrected normal 
range) confirmed by repeated measurements without other explanations”) [8].
4. Indications for intervention
Here, we have to take notice of the patient’s status in order to choose the type 
of intervention and the correct timing of it. Early valve intervention should be 
strongly recommended in all symptomatic patients with severe AS, because it 
is the only effective treatment. “As long as the mean gradient remains >40 mmHg, 
there is virtually no lower ejection fraction limit for intervention, whether surgery 
or TAVI” [8].
However, patients with severe comorbidities indicating a survival of <1 year 
and patients in whom is unlikely that the intervention will improve quality of life or 
survival should be excluded from further interventions.
Asymptomatic patients. There is some disagreement about the optimal timing 
of surgery in asymptomatic patients, and the decision to operate on this kind of 
patient requires careful weighing of the benefits against the risks.
The available studies do not provide convincing data to support the general 
recommendation of early SAVR, even in patients with asymptomatic and very 
severe aortic stenosis, and TAVI is not recommended in asymptomatic patients 
[7, 8]. However, subclinical adverse remodeling can precede the development 
of symptoms and LV dysfunction [16]. Musa et al. performed cardiac magnetic 
resonance (CMR) in 674 patients who had severe AS and were scheduled for 
surgical or transcatheter AVR. Myocardial fibrosis (scar) demonstrated by late 
gadolinium enhancement (LGE) on CMR was common (51%). In a median follow-
up of 3.6 years (interquartile range, 2.6–5.9 years), 21.5% of patients had died. In 
multivariable analysis, scar (LGE positivity) was independently associated with 
all-cause and cardiovascular mortality (hazard ratios, 2.39 and 3.14, respectively). 
The elevated mortality was independent of whether the patients underwent surgical 
or transcatheter AVR and was similar in patients with infarct and noninfarct scar 
patterns. These findings raise the possibility that adverse remodeling has irrevers-
ible effects before symptoms develop: We may be waiting too long to treat these 
patients. The authors suggest that physicians might use scar burden to optimize the 
timing of intervention, a hypothesis currently being evaluated in a randomized trial 
(EVOLVED-AS) [16].
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Early elective surgery is indicated in asymptomatic patients with [8]:
• depressed LV function not due to other causes and in patients who develop 
symptoms during exercise testing
• abnormal exercise test showing symptoms on exercise clearly related to aortic 
stenosis
• abnormal exercise test showing a decrease in blood pressure below baseline
• predictors of symptom development and adverse outcomes: clinical character-
istics (older age, presence of atherosclerotic risk factors), echocardiographic 
parameters (valve calcification, peak aortic jet velocity, LVEF, rate of hemody-
namic progression, increase in mean gradient >20 mmHg with exercise, excessive 
LV hypertrophy, abnormal longitudinal LV function, and pulmonary hyperten-
sion), and biomarkers (>threefold age- and sex-corrected normal range).
• When early elective surgery is considered in patients with normal exercise 
performance because of the presence of such outcome predictors, the operative 
risk should be low. In patients without predictive factors, watchful waiting 
appears safe and early surgery is unlikely to be beneficial.
An update of proposed management strategy for patients with severe AS by Leal 
et al. [17] is shown in Figure 1, based on the ESC/EACTS and ACC/ AHA guidelines 
on the management of valvular heart disease [8, 18].
Figure 1. 
Management of severe aortic stenosis [8, 17, 18]. ACC/AHA recommendations have been shown in parentheses.
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5. Risk stratification
Risk stratification applies to any sort of intervention and is required for weigh-
ing the risk of intervention against the expected natural history of VHD as a basis 
for decision making [8]. Nowadays, the STS score and logistic EuroSCORE II are 
the most commonly used. The EuroSCORE I overestimates operative mortality 
and its calibration of risk is poor, and it should no longer be used to guide deci-
sion making, but it has been used in many TAVI studies/registries and may still 
be useful to identify the subgroups of patients for decision between interven-
tion modalities and to predict 1-year mortality [8]. The EuroSCORE II and the 
Society of Thoracic Surgeons (STS) scores more accurately discriminate high- 
and low-risk surgical patients and show better calibration to predict postoperative 
outcome after valvular surgery [8]. Current models do not include some risk 
factors that may be particularly important in the prediction of outcomes, includ-
ing frailty, pulmonary hypertension (PH), porcelain aorta, and the presence of 
hepatic dysfunction.
New scores have been developed to estimate the risk of 30-day mortality in 
patients undergoing TAVI, with better accuracy and discrimination, but not 
without certain limitations by a lack of consideration of frailty, disability, and 
cognitive function [19]. Examples of those are: FRANCE-2 risk score [20], the STS/
ACC TVT registry predictive model [21], and the TAVR risk score based on data 
from the German aortic valve registry [22]. A new tool based on the STS/ACC TVT 
Registry™ is an application for from the STS/ACC TVT Registry™ an application 
for mobile devices and web, call “TAVR in-hospital mortality Risk app” [23], in 
order to inform physicians of the estimated risk of in-hospital mortality.
It remains essential not to rely on a single risk score figure when assessing 
patients or to determine unconditionally the indication and type of intervention.
The role of the heart team is essential to take all of these data into account and 
adopt a final decision on the best treatment strategy. It is important to take into 
account patient’s life expectancy, expected quality of life, and patient preference, 
as well as local resources, in order to do a proper planning of intervention. There 
is a growing interest in the assessment of frailty, an overall marker of impairment 
of functional, cognitive, and nutritional status. Frailty is associated with increased 
morbidity and mortality after surgery and TAVI [24].
Finally, the patient and family should be thoroughly informed and assisted in 
their decision on the best treatment option.
Actual AHA/ACC guideline classifies patients with severe AS into four global 
risk categories: [19].
1. Low risk: STS <4% with no frailty, no comorbidity, and no procedure-specific 
impediments.
2. Intermediate risk: STS 4-8% with no more than mild frailty or one major 
organ system compromise not to be improved postoperatively and minimal 
procedure-specific impediments.
3. High risk: STS >8%, or moderate-severe frailty, no more than two major 
organ systems compromise not to be improved postoperatively, or a possible 
procedure-specific impediment.
4. Prohibitive risk: preoperative risk of mortality and morbidity >50% at 1 year 
or ≥three major organ systems compromises not to be improved postopera-
tively or severe frailty or severe procedure-specific impediments.
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Thus, the current ESC/EACTS guidelines for the management of valvular 
heart disease [8] consider two global risk categories:
1. Low surgical risk (STS or EuroSCORE II < 4% or logistic EuroSCORE I < 10% 
and no other risk factors not included in these scores, such as frailty, porcelain 
aorta, and sequelae of chest radiation).
2. Increased surgical risk (STS or EuroSCORE II >4% or logistic EuroSCORE 
I > 10% or other risk factors not included in these scores such as frailty, porce-
lain aorta, and sequelae of chest radiation).
A resume of risk categories is shown in Table 2.
In conclusion, the decision to proceed with AVR or TAVI requires careful 
weighing of the potential for improved symptoms and survival and the morbid-
ity and mortality of surgery and should be made by the heart team according 
to the individual patient characteristics. Checklist for choice of therapeutic 
intervention option (Table A1) could be consulted and printed from the addi-
tional material, in order to provide aspects that should be considered for the 
individual decision, based on the current recommendation of de ESC/EACTS 
guidelines.
6. Interventional therapeutic options
6.1 Surgical approach
6.1.1 Conventional AVR
The conventional approach to AVR consists of a mid-line incision and full ster-
notomy, which provide a complete and comfortable access to the heart. Since it was 
first successfully carried out by Harken and Starr in 1960 [26, 27], there has been a 
continuous innovation in prosthetic technology and surgical techniques. All these 
collective efforts have resulted in improvements in both operative and long-term 
results [17]. Regardless of surgical approach, elected AVR is the gold standard for the 
treatment of severe AS. Several studies have shown short- and long-term outcomes, 
Risk assessment tool
Risk category STS score EuroScore II EuroScore
Low risk <4% <4% <10%
Intermediate risk 4–8% >4–7%* >10–20%*
High risk >8% >7* >20%*
Prohibitive risk >50%
*ESC/EACTS guidelines consider two categories (low and increased surgical risk).
Based on 2017 ACC Expert Consensus Decision Pathway for Transcatheter Aortic Valve Replacement in the 
Management of Adults with Aortic Stenosis and the 2017 ESC/EACTS Guidelines for the management of valvular 
heart disease [8, 19, 25].
Table 2. 
Risk assessment tools.
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as well as improved quality of life. Operative outcomes following AVR were still 
improving in the past decade. Wu et al. [28], determined the economic value of 
the additional life given to patients undergoing AVR, and concluded that AVR is 
cost-effective for all ages, and still worthwhile in octogenarian and nonagenarian 
patients.
6.1.2 Minimally invasive surgical (MIS) approaches
Minimally invasive surgery aims to minimize the degree of surgical intrusive-
ness. Currently, there are several surgical approaches. The partial sternotomy 
and right anterior minithoracotomy are the most frequently used incisions for 
a minimally invasive approach to the aortic valve. The choice of interventional 
approach depends on the patient’s anatomy as observed in preoperative imaging 
studies such as CT.
The “J” incision is the most widely used approach among the partial upper 
hemisternotomy approach (Figure 2). Figure 3 shows the access view through right 
anterior minithoracotomy.
Figure 2. 
Partial upper hemisternotomy approach. Operative field distribution from surgeon view [17].
Figure 3. 
Right anterior thoracotomy through 2 or 3° intercostal space [17].
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6.1.2.1 Advantages and disadvantages of MIS approaches in aortic stenosis
Benefits have been observed in certain aspects such as:
• reduction in bleeding and use of hemoderivatives
• reduction in the pain perceived by the patient, which results in reduced 
consumption of analgesic [29–31]
• less respiratory complications such as atelectasis by maintaining the integrity 
of the thorax [32]
• better esthetic results, due to the reduced size of the surgical incisions and 
their relocation to less visible areas [33]
• reduction of the surgical wound infections [34]
• reduction on duration of hospitalization and time spent in intensive care units, 
which results on less expensive cost of the process.
A certain consensus exists around the benefits mentioned above. There is 
also a question of the impact of MIS on duration of surgery. There is disparity in 
the results found in the literature. Once the learning curve has been overcome, 
these times tend to equal out, and there is no significant difference to be observed 
between the different approaches.
6.1.3 Rapid deployment prostheses
Their use in association with MIS approaches, providing a reduction in 
surgical aggression in addition to the reduction in ECC and aortic clamping 
time. These designs have the common feature of being expandable, anchoring 
themselves to the aortic ring in a similar way to the devices used in TAVI. To 
date, there are two commercially available models: Perceval (LivaNova) and 
Intuity (Edwards Lifesciences). Those prostheses differ from each other in a few 
characteristics.
• Perceval (LivaNova): it is useful on patients in which a reduction in surgery 
time may have a paramount impact, or those where it is necessary to carry out 
mixed procedures [35, 36]. A recent multicenter study reports a reduction 
on mean crossclamp and cardiopulmonary bypass times, and a significant 
improvement in clinical status was observed postoperatively in the majority 
of patients [37]. The Perceval valve implantation could be easily performed 
by offering a significant reduction in crossclamping and CPB times compared 
with both the traditional valve prostheses and the other sutureless prosthe-
ses available on the market, even when performed via a minimally invasive 
approach [37]. It remains important for the continuation of the patient’s 
follow-up, in order to provide further assessment of long-term valve perfor-
mance [37].
• Intuity (Edwards Lifesciences): it is made by the conjunction between the 
Edwards Perimount bioprosthesis, the clinical and hemodynamic results 
of which are widely known, and the experience in the development of the 
Sapien transcatheter prosthesis. The mode of implantation for this prosthesis 
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allows the aortic clamping and extracorporeal circulation times to be reduced. 
Reports of early outcomes have shown an important reduction in aortic 
crossclamp and cardiopulmonary bypass (CPB) [38, 39]. These findings were 
confirmed in both the European TRITON [40] and the US TRANSFORM trials 
[41]. Even more important, these times were reduced significantly in combined 
cardiac procedures [38].
6.1.4 Transcatheter aortic valve implantation (TAVI)
TAVI was developed as an alternative to AVR in the very or extremely high-risk 
patient population, and its first implantation in man was performed by Cribier [42] 
in 2002. Since then, there has been a nonstop development of less invasive strategies 
with lower mortality, lower morbidity, and less invasiveness [43].
6.1.4.1 Implantation techniques
TAVI is currently carried out using two main approaches, transfemoral and 
transapical. If this is not feasible, then the other two main approaches could be 
used namely trans-axillary artery or transaortic approaches. It is, therefore, highly 
recommended to perform an adequate preoperative assessment of the degree of 
peripheral arterial disease through imaging studies such as CT.
6.1.4.2 TAVI results
The results of the PARTNER I Cohort A trial also have important implica-
tions. The primary endpoint of the trial was met, with TAVI found not to be 
inferior to aortic valve replacement for all-cause mortality at 1 year. Death at 
30 days was lower than expected in both arms of the trial: TAVI mortality (3.4%) 
was the lowest reported in any series, despite an early generation device and 
limited previous operator experience. Aortic valve replacement mortality (6.5%) 
was lower than the expected operative mortality (11.8%). On 2015, the 5-year 
follow-up result of the PARTNER I trial was published [44]; they screened 3105 
patients, of whom 699 were enrolled (348 assigned to TAVR, 351 assigned to 
SAVR). At 5 years, risk of death was 67·8% in the TAVR group compared with 
62.4% in the SAVR group (hazard ratio 1.04, 95% CI 0.86–1.24; p = 0.76). They 
recorded no structural valve deterioration requiring surgical valve replacement 
in either group. Moderate or severe aortic regurgitation occurred in 40 (14%) 
of 280 patients in the TAVR group and two (1%) of 228 in the SAVR group 
(p < 0.0001), and was associated with the increased 5-year risk of mortality in 
the TAVR group [44].
7.  Intermediate risk patients: who are they? And how do we have to 
manage them?
As we described before, currently AHA/ACC guideline for the management of 
patients with valvular heart disease [7, 19] defines the intermediate-risk patients 
as those who has an STS 4–8% with no more than mild frailty or one major organ 
system compromise not to be improved postoperatively and minimal procedure-
specific impediments. In the other hand, the European guidelines define such 
patient as at “increased surgical risk” (STS or EuroSCORE II >4% or logistic 
EuroSCORE I > 10% or other risk factors not included in these scores such as frailty, 
porcelain aorta, and sequelae of chest radiation) [8].
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This cohort of patients has two therapeutic options, surgical AVR or TAVI, and 
the decision pathway goes through the accurate interpretation of all data by the 
Heart Team.
Nowadays, increased operator experience and enhanced transcatheter valve sys-
tems have led to a worldwide trend to use TAVI in patients who are at low or inter-
mediate risk [45]. This tendency has been evaluated in small observational studies, 
but since most patients who are currently recommended for surgery are at low or 
intermediate risk, the expansion of the use of TAVI demands more rigorous clinical-
trial validation [46]. The intermediate-surgical-risk trials were approved comparing 
TAVI to surgery, with the balloon-expandable SAPIEN XT valve (PARTNER 2 trial) 
and the self-expandable CoreValve (SUrgical Replacement and Transcatheter Aortic 
Valve Implantation trial (SURTAVI trial)) [46, 47].
The PARTNER 2 trial [46] was a multicenter, randomized control trial con-
ducted, which enrolled 2032 patients with severe symptomatic aortic stenosis 
and intermediate-surgical-risk, and randomized them in a 1:1 fashion across the 
TAVI arm and the surgical arm [48]. After 2 years, the all-cause mortality or dis-
abling stroke was similar in the TAVI group and the SAVR group (19.3 vs. 21.1%, 
p = 0.33 and p = 0.001 for noninferiority). In the transfemoral access cohort, 
TAVI demonstrated a lower mortality and disabling stroke (hazard ratio = 0.79; 
95% CI = 0.62–1.00; p = 0.05). TAVI resulted in larger aortic valve areas, lower 
rates of acute kidney injury, severe bleeding, and new-onset atrial fibrillation; 
SAVR resulted in fewer major vascular complications and less paravalvular 
aortic leak [49]. As a result of the PARTNER 2 trial, the current guideline from 
the American Heart Association and American College of Cardiology recom-
mended TAVI as an alternative to surgery in patients at intermediate surgical 
risk [18, 48].
The SURTAVI trial [47] analyzes the self-expanding CoreValve in intermediate-
risk patients and was a randomized, multicenter control trial, which recruited a 
total of 1746 patients [46]. The combined primary endpoint (all-cause mortality 
or disabling stroke) at 24 months was 12.6% in the TAVI group and 14.0% in the 
surgery group. Residual aortic regurgitation and need for pacemaker implantation 
were more frequent among TAVI patients. In the other hand, SAVR was associated 
with the higher rates of atrial fibrillation, acute kidney injury, and transfusion 
requirements. The TAVI resulted in lower mean gradients and larger aortic valve 
areas than surgery did. Structural valve deterioration at 24 months did not occur in 
either group. SURTAVI revealed that CoreValve TAVI was not inferior to surgery in 
patients with intermediate surgical risk [49].
Bicuspid aortic valves: the extreme and asymmetrical calcification noted with 
bicuspid valves can prevent adequate expansion of the valve frame of TAVI valves, 
affecting valve hemodynamics, and leading to higher aortic valve gradients and 
more paravalvular leaks [48].
Prostheses thrombosis: the Portico Re-sheathable Transcatheter Aortic Valve 
System U.S. Investigational Device Exemption (PORTICO IDE) study evaluates 
TAVI with either a Portico valve (St. Jude Medical) or a commercially available 
valve. Computed tomography (CT) was performed in a subgroup of patients to 
assess the stent frame of the implanted valve. A finding of reduced leaflet motion 
on CT in a patient who had had a stroke after TAVI and similar findings in an 
asymptomatic patient at one clinical site led to a closer look of this observation. 
Additional CT review by the core laboratory revealed that this finding was not 
isolated, which prompted a more extensive investigation. This findings encourage 
to create two registries to evaluate the prostheses thrombosis (SAVORY registry and 
RESOLVE registry), and find out that therapeutic anticoagulation with warfarin, 
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but not therapy with antiplatelet drugs, prevented and effectively treated this 
phenomenon. Better characterization of this observation is needed to determine its 
frequency and evaluate its clinical effect [50].
Durability: intermediate surgical-risk patients are expected to survive longer 
after TAVI when compared to higher-risk patients; the broad application of TAVI in 
low-risk patients should be limited until in vivo durability results are available for 
the TAVI prostheses [48]. While structural valve deterioration in surgically replaced 
valves has been thoroughly investigated, long-term follow-up data for TAVI valves 
implanted in patients remain sparse [48].
8. Conclusions
Nowadays, the patients with intermediate risk are in the frontier of TAVI 
and surgical AVR, and more than ever, the heart team has to be more accurate 
to choose between the different treatment options available. Current expansion 
of TAVI into lower surgical risk patients encourages the need to remain cautious 
about unbridled expansion into those patients, as many questions remain about 
valve durability, leaflet thrombosis, and higher rates of paravalvular leak and 
permanent pacemakers [48]. Meanwhile, the surgical approach has improved and 
evolved to a reduction in surgical aggression. TAVI and minimally invasive aortic 
valve replacement [51] have become alternatives to surgical aortic valve replace-
ment via median sternotomy (SAVR) to treat severe aortic stenosis (AS). Despite 
increased interest and utilization, few studies have directly compared TAVI and 
miniAVR. MiniAVR maintains potential advantages over SAVR, including the 
implantation of a durable prosthesis and low rates of perioperative myocardial 
infarction and paravalvular leak. It is associated with longer aortic crossclamp 
and cardiopulmonary bypass (CPB) times; however, the use of rapid deployment 
valves can circumvent this. Studies comparing TAVI and miniAVR demonstrate 
decreased postoperative mortality, valvular regurgitation, and incidence of stroke 
in the miniAVR cohorts [51].
From economic point of view, it is clear that for high-risk operable patients, 
TAVI is currently a more expensive therapy and probably a less effective alterna-
tive to surgical AVR, with an incremental cost-effectiveness ratio (ICER) that may 
be acceptable for high-income countries, but definitely not for the moderate- or 
low-income countries [52]. When use of TAVI is extended to include a larger number 
of moderate- to low-risk patients suitable for AVR, overall economic results become 
less favorable. When manufacturers reduce the exuberant cost of the valve and its 
accessories, TAVI may become the predominant therapy for patients with severe 
aortic stenosis. [52].
Finally, it is clear that both strategies will be the cornerstones in the modern 
AVR era, but the situations in which to apply each strategy have not yet been clearly 
delineated. More studies are needed to compare TAVI and miniAVR in low- and 
intermediate-risk patients. However, the current practice guidelines give a good 
pathway to choose the adequate therapeutic option in each individual case.
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Appendix
Favor 
TAVI
Patient Favor 
AVR
Patient
Clinical characteristic
STS/EuroScore II < 4% (EuroScore I < 10%) +
STS/EuroScore II > 4% (EuroScore I > 10%) +
Severe comorbidities +
Age <75 years +
Age >75 years +
Previous cardiac surgery +
Frailty +
Restricted mobility +
Suspicion of Endocarditis +
Anatomical and technical aspects
Favorable access for transfemoral TAVI +
Unfavorable access for TAVI +
Sequelae of chest radiation +
Porcelain aorta +
Pervious and permeable CABG +
Expected patient-prosthesis mismatch +
Severe chest deformation +
Short distance between coronary ostia and aortic valve annulus +
Aortic root morphology unfavorable for TAVI (Bicuspid valve, 
severe calcification)
+
Undergoing CABG or another cardiac surgery +
Based on 2017 ESC/EACTS guidelines for the management of valvular heart disease [8].
Table A1. 
Checklist for choice of therapeutic intervention option.
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